# Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes

> **NCT02303730** · PHASE4 · COMPLETED · sponsor: **Fudan University** · enrollment: 76 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2
- Non-alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** Exenatide
- **DRUG:** insulin glargine

## Key facts

- **NCT ID:** NCT02303730
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2017-11
- **Final completion:** 2017-11
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2019-08-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02303730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02303730, "Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes". Retrieved via MORVS 2026-11-02 from https://api.morvs.ai/clinical/NCT02303730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*